



European Heart Journal Supplements

Volume 11 Supplement C June 2009

Preface	C1
Reaching new horizons and the politic imperative of ST-segment elevation myocardial infarction care <i>J.M. Hill and G.J. Laarman</i>	C2
New paradigms of care for STEMI focusing on mortality and attributable death analysis: what do device and drug trials teach us? <i>R. Mehran and G.W. Stone</i>	C4
Bleeding management and pharmacological strategy in primary percutaneous coronary intervention <i>C.W. Hamm</i>	C9
Does 'SWITCHing' from heparin to bivalirudin monotherapy result in a bleeding benefit? <i>Z. Astroulakis and J.M. Hill</i>	C13
Emerging data and decision for optimizing STEMI management: the European perspective <i>G. Guagliumi</i>	C19
Optimizing outcomes in patients with STEMI: mortality, bleeding, door-to-balloon times, and guidelines: the approach to regional systems for STEMI care: defining the ideal approach to reperfusion therapy based on recent trials <i>N. Danchin, R. Carda, A. Chaib, A. Lepillier, and E. Durand</i>	C25
Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist—from evidence to recommendations and practice <i>F. Van de Werf</i>	C31



www.eurheartj.org